VYNE Therapeutics Concludes Patient Enrolment in Mid-Stage Study Of Skin Inflammation Candidate
June 17, 2022 at 10:41 AM EDT
VYNE Therapeutics Inc. (NASDAQ: VYNE) has concluded patient enrollment in the Phase 2a study of of its drug candidate FMX114 for the ...